Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis

Clinical Gastroenterology and Hepatology

Volumn 16, Issue 9, 2018, Pages 1511-1520.e5

  Ajmera, Veeral ^a,c   Belt, Patricia ^b   Wilson, Laura A ^b   Gill, Ryan M ^a   Loomba, Rohit ^c   Kleiner, David E ^d   Neuschwander Tetri, Brent A ^e   Terrault, Norah ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e SAINT LOUIS UNIVERSITY   (United States)

Author keywords

Cohort Study; Fatty Liver; Long Term; Resolution

Indexed keywords

ASPARTATE AMINOTRANSFERASE;

ADULT; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOL USE DISORDERS IDENTIFICATION TEST; ANALYSIS OF VARIANCE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BEHAVIOR DISORDER ASSESSMENT; CAUCASIAN; CLINICAL RESEARCH; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; FATTY LIVER; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFORMATION PROCESSING; LIVER BIOPSY; LIVER FIBROSIS; LOGISTIC REGRESSION ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; ODDS RATIO; QUESTIONNAIRE; SKINNER LIFETIME DRINKING HISTORY; ADOLESCENT; ADVERSE EVENT; AGED; CYTOCHEMISTRY; DRINKING BEHAVIOR; MIDDLE AGED; PATHOLOGY; REMISSION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALCOHOL DRINKING; FEMALE; HISTOCYTOCHEMISTRY; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; REMISSION, SPONTANEOUS; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 85048307469     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2018.01.026     Document Type: Article

References (29)

1. Williams, C.D., Stengel, J., Asike, M.I., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140 (2011), 124–131.
2. Ong, J.P., Pitts, A., Younossi, Z.M., Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 49 (2008), 608–612.
3. Thun, M.J., Peto, R., Lopez, A.D., et al. Alcohol consumption and mortality among middle-aged and elderly U.S. adults. N Engl J Med 337 (1997), 1705–1714.
4. Saad L. Majority in U.S. drink alcohol, averaging four drinks a week: beer edges out wine by 39% to 35% as drinkers’ beverage of choice. Available at http://news.gallup.com/poll/156770/majority-drink-alcohol-averaging-four-drinks-week.aspx. Accessed: June 1, 2017.
5. Tian, C., Stokowski, R.P., Kershenobich, D., et al. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet 42 (2010), 21–23.
6. Romeo, S., Kozlitina, J., Xing, C., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40 (2008), 1461–1465.
7. Zhu, L., Baker, R.D., Zhu, R., et al. Gut microbiota produce alcohol and contribute to NAFLD. Gut, 65, 2016, 1232.
8. Davies, M.J., Baer, D.J., Judd, J.T., et al. Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women: a randomized controlled trial. JAMA 287 (2002), 2559–2562.
9. Sookoian, S., Castano, G.O., Pirola, C.J., Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: a meta-analysis of 43 175 individuals. Gut 63 (2014), 530–532.
10. Moriya, A., Iwasaki, Y., Ohguchi, S., et al. Roles of alcohol consumption in fatty liver: a longitudinal study. J Hepatol 62 (2015), 921–927.
11. Dunn, W., Sanyal, A.J., Brunt, E.M., et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol 57 (2012), 384–391.
12. Cotrim, H.P., Freitas, L.A., Alves, E., et al. Effects of light-to-moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients. Eur J Gastroenterol Hepatol 21 (2009), 969–972.
13. Neuschwander-Tetri, B.A., Clark, J.M., Bass, N.M., et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 52 (2010), 913–924.
14. Sanyal, A.J., Chalasani, N., Kowdley, K.V., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362 (2010), 1675–1685.
15. Chalasani, N.P., Sanyal, A.J., Kowdley, K.V., et al. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials 30 (2009), 88–96.
16. Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385 (2015), 956–965.
17. Kleiner, D.E., Brunt, E.M., Van Natta, M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005), 1313–1321.
18. Kwon, H.K., Greenson, J.K., Conjeevaram, H.S., Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease. Liver Int 34 (2014), 129–135.
19. Dixon, J.B., Bhathal, P.S., O'Brien, P.E., Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121 (2001), 91–100.
20. Mukamal, K.J., Ding, E.L., Djousse, L., Alcohol consumption, physical activity, and chronic disease risk factors: a population-based cross-sectional survey. BMC Public Health, 6, 2006, 118.
21. Sookoian, S., Flichman, D., Castaño, G.O., et al. Mendelian randomisation suggests no beneficial effect of moderate alcohol consumption on the severity of nonalcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics 44 (2017), 1224–1234.
22. Hoofnagle, J.H., Van Natta, M.L., Kleiner, D.E., et al. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 38 (2013), 134–143.
23. Nanau, R.M., Neuman, M.G., Biomolecules and biomarkers used in diagnosis of alcohol drinking and in monitoring therapeutic interventions. Biomolecules 5 (2015), 1339–1385.
24. Stockwell, T., Donath, S., Cooper-Stanbury, M., et al. Under-reporting of alcohol consumption in household surveys: a comparison of quantity–frequency, graduated–frequency and recent recall. Addiction 99 (2004), 1024–1033.
25. Ekstedt, M., Hagstrom, H., Nasr, P., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61 (2015), 1547–1554.
26. Singh, S., Allen, A.M., Wang, Z., et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 13 (2015), 643–654.
27. Unalp-Arida, A., Ruhl, C.E., Noninvasive fatty liver markers predict liver disease mortality in the U.S. population. Hepatology 63 (2016), 1170–1183.
28. VanWagner, L.B., Ning, H., Allen, N.B., et al. Alcohol use and cardiovascular disease risk in patients with nonalcoholic fatty liver disease. Gastroenterology 153 (2017), 1260–1272.
29. Rotman, Y., Koh, C., Zmuda, J.M., et al. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 52 (2010), 894–903.